You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 10, 2024

Investigational Drug Information for Seladelpar


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Seladelpar?

Seladelpar is an investigational drug.

There have been 11 clinical trials for Seladelpar. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.

The most common disease conditions in clinical trials are Cholangitis, Liver Cirrhosis, Biliary, and Liver Diseases. The leading clinical trial sponsors are CymaBay Therapeutics, Inc. and [disabled in preview].

There are twenty-one US patents protecting this investigational drug and three hundred and one international patents.

Recent Clinical Trials for Seladelpar
TitleSponsorPhase
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisCymaBay Therapeutics, Inc.Phase 3
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)CymaBay Therapeutics, Inc.Phase 3
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)CymaBay Therapeutics, Inc.Phase 1

See all Seladelpar clinical trials

Clinical Trial Summary for Seladelpar

Top disease conditions for Seladelpar
Top clinical trial sponsors for Seladelpar

See all Seladelpar clinical trials

US Patents for Seladelpar

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Seladelpar ⤷  Sign Up Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Sign Up
Seladelpar ⤷  Sign Up Medical use of pharmaceutical combination or composition Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Sign Up
Seladelpar ⤷  Sign Up Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome Boehringr Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Sign Up
Seladelpar ⤷  Sign Up Treatment of intrahepatic cholestatic diseases CymaBay Therapeutics, Inc. ⤷  Sign Up
Seladelpar ⤷  Sign Up 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs Janssen Pharmaceutical N.V. (Beerse, BE) ⤷  Sign Up
Seladelpar ⤷  Sign Up 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs Janssen Pharmaceutica NV (Beerse, BE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Seladelpar

Drugname Country Document Number Estimated Expiration Related US Patent
Seladelpar Australia AU2011249722 2030-05-05 ⤷  Sign Up
Seladelpar Brazil BR112012028136 2030-05-05 ⤷  Sign Up
Seladelpar Canada CA2797310 2030-05-05 ⤷  Sign Up
Seladelpar Canada CA3070513 2030-05-05 ⤷  Sign Up
Seladelpar Chile CL2012003053 2030-05-05 ⤷  Sign Up
Seladelpar China CN102946875 2030-05-05 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.